Literature DB >> 16042980

The AT2 receptor--a matter of love and hate.

U M Steckelings1, E Kaschina, Th Unger.   

Abstract

In 1989, the development of specific angiotensin receptor antagonists which distinguish between two angiotensin receptor subtypes (AT1 and AT2) led to a breakthrough in angiotensin research. It turned out, that the AT1 receptor was almost entirely responsible for the "classical" actions of angiotensin II related to the regulation of blood pressure as well as volume and electrolyte balance. However, actions and signal transduction mechanisms coupled to the AT2 receptor remained enigmatic for a long time. The present review summarizes the current knowledge of AT2 receptor distribution, signaling and function with an emphasis on growth/anti-growth, differentiation and the regeneration of neuronal tissue.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16042980     DOI: 10.1016/j.peptides.2005.03.010

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  68 in total

Review 1.  Key advances in antihypertensive treatment.

Authors:  Ludovit Paulis; Ulrike M Steckelings; Thomas Unger
Journal:  Nat Rev Cardiol       Date:  2012-03-20       Impact factor: 32.419

2.  Gene expression profiles linked to AT1 angiotensin receptors in the kidney.

Authors:  Natalia A Makhanova; Steven D Crowley; Robert C Griffiths; Thomas M Coffman
Journal:  Physiol Genomics       Date:  2010-08-31       Impact factor: 3.107

Review 3.  Novel therapeutic targets for hypertension.

Authors:  Ludovit Paulis; Thomas Unger
Journal:  Nat Rev Cardiol       Date:  2010-06-22       Impact factor: 32.419

Review 4.  Role of angiotensin II receptor subtype activation in cognitive function and ischaemic brain damage.

Authors:  Masatsugu Horiuchi; Masaki Mogi
Journal:  Br J Pharmacol       Date:  2011-07       Impact factor: 8.739

Review 5.  International Union of Basic and Clinical Pharmacology. XCIX. Angiotensin Receptors: Interpreters of Pathophysiological Angiotensinergic Stimuli [corrected].

Authors:  Sadashiva S Karnik; Hamiyet Unal; Jacqueline R Kemp; Kalyan C Tirupula; Satoru Eguchi; Patrick M L Vanderheyden; Walter G Thomas
Journal:  Pharmacol Rev       Date:  2015-10       Impact factor: 25.468

Review 6.  Angiotensin-converting enzymes and drug discovery in cardiovascular diseases.

Authors:  Lijun Shi; Caiping Mao; Zhice Xu; Lubo Zhang
Journal:  Drug Discov Today       Date:  2010-02-17       Impact factor: 7.851

7.  Modification of gene expression profiling related to renin-angiotensin system in an ischemia/reperfusion rat model after T3 infusion.

Authors:  Laura Sabatino; Silvana Balzan; Claudia Kusmic; Giorgio Iervasi
Journal:  Mol Cell Biochem       Date:  2018-05-08       Impact factor: 3.396

8.  Brain angiotensin and dopaminergic degeneration: relevance to Parkinson's disease.

Authors:  Jose L Labandeira-Garcia; Jannette Rodriguez-Pallares; Ana I Rodríguez-Perez; Pablo Garrido-Gil; Begoña Villar-Cheda; Rita Valenzuela; Maria J Guerra
Journal:  Am J Neurodegener Dis       Date:  2012-11-18

Review 9.  RAS blockade with ARB and ACE inhibitors: current perspective on rationale and patient selection.

Authors:  Christian Werner; Magnus Baumhäkel; Koon K Teo; Roland Schmieder; Johannes Mann; Thomas Unger; Salim Yusuf; Michael Böhm
Journal:  Clin Res Cardiol       Date:  2008-05-03       Impact factor: 5.460

10.  Angiotensin II subtype 2 receptor blockade and deficiency attenuate the development of atherosclerosis in an apolipoprotein E-deficient mouse model of diabetes.

Authors:  A Koïtka; Z Cao; P Koh; A M D Watson; K C Sourris; L Loufrani; A Soro-Paavonen; T Walther; K J Woollard; K A M Jandeleit-Dahm; M E Cooper; T J Allen
Journal:  Diabetologia       Date:  2009-12-03       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.